Multi-center prospective clinical study initiated by Carmentix in Australia, China and Hong Kong

In a follow up to the successful retrospective clinical study which concluded with the University of Melbourne (UoM) in August 2017, we now embark on a multi-center prospective clinical study with UoM, The Chinese University Hong Kong (CUHK) and The Henan Province People's Hospital.

The multi-center prospective clinical study will allow us to validate Carmentix's proprietary biomarkers in conjunction with UoM's previously discovered biomarkers. These biomarkers were found to be strongly associated with labor in the previous retrospective study.

The collaboration with UoM, CUHK and The Henan Province People's Hospital will provide one of the largest bio-bank of preterm birth samples. We aim to collect over 15000 samples in the next 2 to 3 years with the help from a dedicated team of clinicians, midwives and scientists. This allows us to pursue the full potential of our biomarkers in a bid to provide a solution to early preterm birth prediction.

Read our media release for more:

http://www.prnewswire.co.uk/news-releases/carmentix-announces-collaboration-for-clinical-preterm-birth-study-685890621.html